SCHAUMBURG, Ill., Nov. 04, 2025 (GLOBE NEWSWIRE) -- An earlier version of this release issued on November 4, 2025, misstated the nature of the share issuance. The release has been corrected to reflect that Sagtec Global Limited issued the shares to Kinetic Seas Incorporated. The corrected release follows: Kinetic Seas Incorporated (OTCQB: KSEZ), a leader in artificial intelligence and the developer of the Skilliks AI platform, today announced the execution of a landmark addendum significantly expanding its ...

New Engage, LinguaAI, and Journey Insights solutions bring multilingual, measurable, and human-like communication to healthcare organizationsOMAHA, Neb., Nov. 04, 2025 (GLOBE NEWSWIRE) -- WestCX, part of West Technology Group, today announced the launch of Engage, the next generation of its AI-native engagement platform. The launch unites Engage, LinguaAI, and Journey Insights into a single ecosystem that enables healthcare organizations to deliver intelligent, multilingual, and measurable patient experienc ...

监管审批里程碑 - Sequel II CNDx系统获得中国国家药品监督管理局（NMPA）的三类医疗器械注册批准，这是通过与贝瑞基因的长期合作实现的[1] - 此次批准标志着全球首个临床级长读长测序仪获得监管许可，预示着中国精准医学和高精度基因组检测进入新纪元[2] - 贝瑞基因由此成为全球首家获授权在临床环境中部署长读长测序平台的公司[6] 技术与产品优势 - 该系统利用单分子实时测序技术，能够提供超过20kb的长读长和高准确性，是唯一能同时实现这两项优势的技术[5] - 与贝瑞基因新获批的地中海贫血临床检测试剂及软件系统结合，为中国医院和诊断实验室提供了首个端到端的长读长测序工作流程[4] - 该技术能在单次测试中全面捕获基因组信息，包括单核苷酸变异、插入缺失、拷贝数变异、结构变异和重复扩增，尤其适用于短读长测序难以检测的复杂变异类型[2][3][5] 市场与应用前景 - 该工作流程针对携带者筛查、产前诊断、新生儿筛查和罕见病检测进行了优化[4] - 贝瑞基因计划将此项能力扩展到更多临床检测领域，如先天性肾上腺皮质增生症、脆性X染色体综合征、脊髓性肌萎缩症、杜氏肌营养不良症等复杂单基因疾病[6] - 此次批准推动了中国临床基因组学生态系统的进步，使实验室能够进行国内检测，与现有技术相比，有望缩短周转时间并提高诊断率[6]

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD. Details of the poster presentation are as follows: Title: A Phase II Trial of Combination Locoregional Chemoimmunot ...

CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that preclinical data from CR-001, its PD-1 x VEGF bispeci ...

Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces it will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer (SITC) conference being held November 5-9, 2025 in National Harbor, Md. The poster ...

公司整体业绩表现 - 公司在截至2025年9月30日的三个月内，几乎所有业务线的处理和交易量均创下纪录 [1] - 公司实现了所有运营部门的运营指标连续增长，并创下七项季度历史记录 [2] - 通过所有支付渠道处理的交易量达到创纪录的1620万笔 [8] ACH业务表现 - ACH部门在所有处理和交易指标上均创下季度纪录 [3] - 无密码借记服务在处理的交易笔数和金额上均创历史纪录，同比分别增长96%和87% [3] - 电子支票交易量和处理的退票交易量在本季度均创下历史纪录 [9] - 公司所有ACH产品均实现了强劲的连续和同比增长，电子支票交易量和处理金额已连续八个季度实现同比增长 [9] - 电子支票交易量同比增长26%，环比增长9%；电子支票处理金额同比增长8%，环比增长15% [7] 卡处理业务表现（包括PayFac） - 信用卡处理交易量创下季度历史纪录，同比增长19%，环比大幅增长75% [5] - 信用卡处理金额为公司历史第二高，同比增长3%，环比增长12% [5] 卡发行业务表现 - 预付卡加载金额环比增长15%，但同比下降46% [6] - 预付卡交易量环比增长18%，但同比下降33% [6] - 预付卡购买量环比增长9%，但同比下降21% [6] - 第三季度总美元加载额超过7500万美元，虽低于去年同期，但持续实现连续增长 [6] 输出解决方案业务表现 - 处理及邮寄的交易/件数环比增长1%，同比下降6% [10] - 处理并交付的电子文件数量环比持平，同比增长3% [10] - 本季度仅电子方式交付的文件达2000万份，处理并交付的总邮件数量超过540万件 [10] 业务战略与市场定位 - 强劲表现反映了市场对公司多样化产品和解决方案日益增长的兴趣，以及Usio One战略的持续成功 [3] - 公司是一家领先的基于云的集成金融科技电子支付解决方案提供商，为商户、账单开具方、银行等提供广泛的支付解决方案 [11] - 公司优势在于能够为卡片发行、支付受理和账单支付提供定制解决方案，并在卡片发行领域拥有独特技术 [11]

CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thom ...

Riot Produces 437 Bitcoin in October 2025CASTLE ROCK, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ: RIOT) (“Riot” or “the Company”), a Bitcoin-driven industry leader in the development of large-scale data centers and bitcoin mining applications, announces unaudited production and operations updates for October 2025. Bitcoin Production and Operations Updates for October 2025 Comparison (%)Metric October 20251September 20251October 20241Month/Month<td style="border-right: ...

New research finds that social media is the number one source for holiday gift inspiration for Gen Z and Millennials73% of shoppers plan to contact a brand on social media this holiday seasonA large majority of consumers are comfortable with companies using AI to deliver better customer care CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- New research from Sprout Social (NASDAQ: SPT), an industry-leading provider of social media management and analytics software, reveals that social media is a leading hub for sh ...